
INTELLECTUAL ABILITY IN THE DUCHENNE
MUSCULAR DYSTROPHY AND DYSTROPHIN GENE
MUTATION LOCATION Milic Rasic V1,2,*, Vojinovic D1, Pesovic J3, Mijalkovic G1, Lukic V1, Mladenovic J1,
Kosac A1, Novakovic I4, Maksimovic N4, Romac S3, Todorovic S1, Savic Pavicevic D3 *Corresponding Author: Vedrana Milic Rasic, M.D., Ph.D., Clinic for Neurology and Psychiatry for Children
and Youth, Dr. Subotica 6A, 11000 Belgrade, Serbia. Tel: +381-11-265-8355. Fax: +381-11-264-5064. E-mail:
vedrana.milic.npk@gmail.com page: 25
|
RESULTS
Clinical and Genetic Characteristics. Fortyone
patients with genetically confirmed deletion or
duplication in the DMD gene and cognitive status
assessment were recruited at the Clinic for Neurology
and Psychiatry for Children and Youth in Belgrade,
Serbia. All affected patients were males, aged 3 to 16
(8.34 ± 2.56) years. Deletions were confirmed in 37
patients (90.24%), while duplications were identified
in four patients (9.75%). The identified deletions and
duplications, description of the mutations at cDNA
and protein level, mutation effect on reading frame, as
well as dystrophin isoforms impaired by mutation, the
age at the onset of disease, the age at psychological
testing and data of the psychological exploration are
shown in Table 1. Although patients with in-frame
mutations could express milder phenotypes, all our
patients with in-frame mutations developed a DMD
phenotype: one patient showed delayed psychomotor
development and was wheelchair-bound at the age of
10 (ID 28), the second had the onset of the disease at
the age of 3.5 years and developed positive Gowers
sign at the age of 7 (ID 5), and two boys, the youngest
one (IDs 2 and 38), expressed initial signs of motor
decline at the age of 6.
The FSIQ was estimated for 37 participants, DQ
was estimated for two patients, while SQ was assessed for two patients. The patients with estimated
DQ and SQ were excluded from statistical analysis
and they are described separately (Table 2).
General intelligence evaluation of the analyzed
population demonstrated statistically significant
difference from population normative values (t =
–4.024, p = 0.00015). The FSIQ with mean of 87.57
(SD 18.79) had a broad range of values between
44.0 and 118.0. Thirteen patients (35.14%) had FSIQ
lower than 85, of whom six patients (16.22%) had
borderline intelligence levels (70
|
|
|
|



 |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|
|